Masimo (MASI) Releases FY18 Earnings Guidance

Masimo (NASDAQ:MASI) updated its FY18 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $2.92 from $2.90 for the period, compared to the Thomson Reuters consensus estimate of $2.91. The company issued revenue guidance of $854 million from $850 million, compared to the consensus revenue estimate of $851.38 million.Masimo also updated its FY 2018 guidance to $2.92-2.92 EPS.

Several research analysts have recently commented on MASI shares. Stifel Nicolaus lifted their price objective on Masimo from $112.00 to $145.00 and gave the stock a buy rating in a report on Tuesday, October 2nd. Needham & Company LLC started coverage on Masimo in a report on Friday, September 14th. They issued a buy rating on the stock. BidaskClub upgraded Masimo from a buy rating to a strong-buy rating in a report on Friday, August 17th. Finally, Zacks Investment Research downgraded Masimo from a buy rating to a hold rating in a report on Wednesday, August 1st. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $109.20.

Shares of MASI traded up $0.03 during trading hours on Wednesday, hitting $115.60. The company had a trading volume of 613,541 shares, compared to its average volume of 517,413. The company has a market cap of $5.88 billion, a P/E ratio of 47.18, a P/E/G ratio of 2.64 and a beta of 1.01. Masimo has a 52-week low of $80.69 and a 52-week high of $126.89.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Wednesday, August 1st. The medical equipment provider reported $0.73 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.02. Masimo had a return on equity of 21.49% and a net margin of 15.30%. The firm had revenue of $211.62 million for the quarter, compared to the consensus estimate of $207.85 million. During the same quarter in the previous year, the business earned $0.83 earnings per share. The company’s quarterly revenue was up 10.0% on a year-over-year basis. Analysts expect that Masimo will post 2.9 earnings per share for the current year.

In related news, CEO Joe E. Kiani sold 29,273 shares of the business’s stock in a transaction dated Thursday, August 2nd. The stock was sold at an average price of $109.08, for a total transaction of $3,193,098.84. Following the transaction, the chief executive officer now owns 168,514 shares in the company, valued at approximately $18,381,507.12. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Ramshorst David J. Van sold 1,325 shares of the business’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $125.00, for a total value of $165,625.00. Following the transaction, the insider now owns 2,325 shares in the company, valued at approximately $290,625. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 763,380 shares of company stock worth $90,518,456. 12.60% of the stock is owned by company insiders.

Masimo Company Profile

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Recommended Story: Risk Tolerance

Earnings History and Estimates for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply